Phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib plus everolimus in metastatic renal cell carcinoma | Dr James Larkin at Annual Meeting 2015 - 101271

Spotlight
Video

Phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib plus everolimus in metastatic renal cell carcinoma | Dr James Larkin at Annual Meeting 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, discusses the results of a phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lenvatinib is an oral tyrosine kinase inhibitor of the VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT signaling networks.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 06/30/15
Added : 3 years ago
Category : Kidney Cancer



Recommended

Nothing found.

More From EMJ

Nothing found.